CSIMarket
 


Abbvie inc   (ABBV)
Other Ticker:  
 

Abbvie Inc 's Leverage Ratio

ABBV's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -0.41%, in IV Quarter 2023 ,Leverage Ratio deteriorated to 8.66 is above the company's typical Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 91 other companies have achieved lower Leverage Ratio than Abbvie Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 1570, from total ranking in the third quarter 2023 at 3150 .

Explain Leverage Ratio?
Who are ABBV Customers?
What are ABBV´s Total Liabilities?


ABBV Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -39.86 % -24.32 % -12.19 % -18.46 % 11.99 %
Y / Y Total Liabilities Change 1.54 % -2.9 % -30.25 % -29.97 % -30.76 %
Leverage Ratio MRQ 8.66 7.46 6.83 6.53 5.13
ABBV's Total Ranking # 1570 # 3150 # 1893 # 1362 # 827
Seq. Equity Change -14.28 % -5.96 % -3.04 % -23.05 % 7.86 %
Seq. Total Liabilities Change -0.41 % 2.67 % 1.35 % -2.02 % -4.76 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 92
Healthcare Sector # 233
Overall Market # 1570


Leverage Ratio Statistics
High Average Low
18.52 7.11 1.29
(Mar 31 2018)   (March 31, 2010)




Financial Statements
Abbvie Inc 's Equity $ 10,397 Millions Visit ABBV's Balance sheet
Abbvie Inc 's Total Liabilities $ 90,072 Millions Visit ABBV's Balance sheet
Source of ABBV's Sales Visit ABBV's Sales by Geography


Cumulative Abbvie Inc 's Leverage Ratio

ABBV's Leverage Ratio for the trailling 12 Months

ABBV Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -39.86 % -24.32 % -12.19 % -18.46 % 11.99 %
Y / Y Total Liabilities TTM Growth 1.54 % -2.9 % -30.25 % -29.97 % -30.76 %
Leverage Ratio TTM 7.3 6.37 6 6.44 6.72
Total Ranking TTM # 53 # 131 # 3499 # 102 # 3625
Seq. Equity TTM Growth -14.28 % -5.96 % -3.04 % -23.05 % 7.86 %
Seq. Total Liabilities TTM Growth -0.41 % 2.67 % 1.35 % -2.02 % -4.76 %


On the trailing twelve months basis Despite of the repayements of liabilities of -0.41% in the trailing twelve months ending in IV Quarter 2023, Leverage Ratio improved to 7.3, below Abbvie Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 15, during the past 12 months, other companies have achieved lower Leverage Ratio than Abbvie Inc . While Leverage Ratio total ranking has improved so far to 53, from total ranking in previous 12 month period at 131.

Explain Leverage Ratio?
Who are ABBV Customers?
What are ABBV´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 24
Within the Market # 53


trailing twelve months Leverage Ratio Statistics
High Average Low
112.82 10.79 1.42
(Sep 30 2018)   (June 30. 2012)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Nascent Biotech Inc  20.05 $ 0.609  Millions$ 0.030  Millions
Eterna Therapeutics Inc   20.01 $ 44.683  Millions$ 2.233  Millions
Abbvie inc   8.66 $ 90,072.000  Millions$ 10,397.000  Millions
Blueprint Medicines Corporation  7.03 $ 918.641  Millions$ 130.609  Millions
Ionis Pharmaceuticals Inc  6.73 $ 2,603.386  Millions$ 386.686  Millions
Bio path Holdings inc   6.30 $ 2.779  Millions$ 0.441  Millions
Mersana Therapeutics Inc   5.13 $ 189.156  Millions$ 36.904  Millions
Biofrontera Inc   4.83 $ 23.139  Millions$ 4.793  Millions
Collegium Pharmaceutical Inc   4.82 $ 941.753  Millions$ 195.431  Millions
Eli Lilly And Company  4.69 $ 50,993.800  Millions$ 10,863.700  Millions
Gossamer Bio Inc   3.97 $ 249.147  Millions$ 62.769  Millions
Amicus Therapeutics inc   3.86 $ 617.706  Millions$ 160.174  Millions
Biolinerx Ltd   3.83 $ 50.702  Millions$ 13.223  Millions
Teva Pharmaceutical Industries Limited  3.65 $ 29,667.000  Millions$ 8,126.000  Millions
Milestone Pharmaceuticals inc   3.49 $ 58.455  Millions$ 16.771  Millions
Travere Therapeutics Inc   2.93 $ 588.103  Millions$ 200.810  Millions
Clene Inc   2.91 $ 38.951  Millions$ 13.390  Millions
Arcutis Biotherapeutics Inc   2.85 $ 252.698  Millions$ 88.667  Millions
Soligenix inc   2.84 $ 7.153  Millions$ 2.522  Millions
Aytu Biopharma Inc   2.80 $ 92.052  Millions$ 32.853  Millions
G1 Therapeutics Inc   2.43 $ 86.154  Millions$ 35.386  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Phibro Animal Health Corporation  2.31 $ 626.625  Millions$ 270.803  Millions
Vaxxinity Inc   2.30 $ 30.902  Millions$ 13.409  Millions
Bristol myers Squibb Company  2.23 $ 65,729.000  Millions$ 29,485.000  Millions
Eyenovia inc   2.05 $ 18.488  Millions$ 8.999  Millions
Alimera Sciences Inc   2.00 $ 92.218  Millions$ 46.170  Millions
Biovie Inc   1.87 $ 13.981  Millions$ 7.491  Millions
Zoetis Inc   1.86 $ 9,289.000  Millions$ 4,991.000  Millions
Emergent Biosolutions Inc   1.81 $ 1,173.900  Millions$ 649.300  Millions

Date modified: 2024-02-21T12:06:42+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com